The US Supreme Court has ruled to continue the widespread accessibility of mifepristone, a medication used for early pregnancy termination. The ongoing appeals process challenged the approval of the drug by the US Food and Drug Administration (FDA) in 2000, with doctors and medical groups claiming that the drug regimen is “unsafe.”
On April 7, a Texas federal district court halted the FDA’s approval of mifepristone, which has been used in half of all US abortions and miscarriage care for over two decades. The ruling was partially blocked on appeal less than a week later, allowing the abortion drug to remain available on a limited basis while an ongoing legal dispute is settled. The ruling permits partial access to the abortion drug, albeit with new restrictions, limiting its use up to seven weeks of pregnancy and disallowing mail distribution.
The recent Supreme Court ruling ensures that mifepristone remains widely available during the ongoing litigation, with the case slated to return to the Fifth Circuit for oral argument next month. Justices Clarence Thomas and Samuel Alito disagreed with the ruling, with the former stating that he would have denied the application for stays, while the latter provided a dissenting opinion from the grant of applications for stays. Thomas provided no further argument, while Alito argued that the applicants had failed to demonstrate the likelihood of irreparable harm and accused the FDA of leveraging court injunctions to evade agency procedures and judicial review.
US President Joe Biden stated on Friday evening, lauding the decision and vowing to continue advocating for women’s reproductive rights. The Biden Administration has broadly criticized the lower courts’ rulings in this case and has vowed to seek emergency relief to protect Americans’ access to safe and effective reproductive care.
This decision comes amid conflicting rulings, with anti-abortion rights groups challenging the FDA’s approval of mifepristone, while 17 states, along with the District of Columbia, fight to preserve access to the medication. The same day the federal district court ended the FDA’s approval, another judge in Washington State ordered the FDA to maintain the drug’s availability in 17 states and the District of Columbia.
The ongoing legal battles over mifepristone are part of a broader policy debate over abortion rights in the US. Pro-life advocates are pushing for restricted abortion access, while pro-choice defenders are fighting to maintain it. These debates have intensified after the US Supreme Court’s 2021 Dobbs v. Jackson Women’s Health Organization ruling, which upended the landmark 1973 Roe v. Wade case, which had previously enshrined a woman’s right to abortion under the constitutional right to privacy, legalizing it nationwide.
In conclusion, the US Supreme Court’s recent decision to uphold the accessibility of mifepristone during ongoing litigation is a significant development in the ongoing battle for reproductive rights in the US. This decision ensures that women will continue to have access to safe and effective reproductive care while the legal disputes surrounding mifepristone are settled. However, the broader policy debates over abortion rights in the US will likely continue as pro-life and pro-choice advocates clash over the future of reproductive rights in the country.